Back to Search
Start Over
1,4-Disubstituted Piperazin-2-Ones as Selective Late Sodium Current Inhibitors with QT Interval Shortening Properties in Isolated Rabbit Hearts.
- Source :
-
Journal of medicinal chemistry [J Med Chem] 2024 Aug 08; Vol. 67 (15), pp. 12676-12694. Date of Electronic Publication: 2024 May 17. - Publication Year :
- 2024
-
Abstract
- Late sodium current ( I <subscript>Na</subscript> ) inhibitors are a new subclass of antiarrhythmic agents. To overcome the drawbacks, e.g., low efficacy and inhibition effect on K <superscript>+</superscript> current, of the FDA-approved late I <subscript>Na</subscript> inhibitor ranolazine, chain amide 6a - 6q , 1,4-disubstituted piperazin-2-ones 7a - 7s , and their derivatives 8a - 8n were successively designed, synthesized, and evaluated in vitro on the Na <subscript>V</subscript> 1.5-transfected HEK293T cells by the whole-cell patch clamp recording assay at the concentration of 40 μM. Among the new skeleton compounds, 7d showed the highest efficacy (IC <subscript>50</subscript> = 2.7 μM) and good selectivity (peak/late ratio >30 folds), as well as excellent pharmacokinetics properties in mice ( T <subscript>1/2</subscript> of 3.5 h, F = 90%, 3 mg/kg, po). It exhibited low hERG inhibition and was able to reverse the ATX-II-induced augmentation of late I <subscript>Na</subscript> phenotype of LQT3 model in isolated rabbit hearts. These results suggest the application potentials of 7d in the treatments of arrhythmias related to the enhancement of late I <subscript>Na</subscript> .
- Subjects :
- Animals
Rabbits
HEK293 Cells
Humans
Anti-Arrhythmia Agents pharmacology
Anti-Arrhythmia Agents chemistry
Anti-Arrhythmia Agents pharmacokinetics
Anti-Arrhythmia Agents chemical synthesis
Sodium Channel Blockers pharmacology
Sodium Channel Blockers chemistry
Sodium Channel Blockers chemical synthesis
Sodium Channel Blockers pharmacokinetics
Mice
Long QT Syndrome chemically induced
Structure-Activity Relationship
Male
NAV1.5 Voltage-Gated Sodium Channel metabolism
Heart drug effects
Ether-A-Go-Go Potassium Channels antagonists & inhibitors
Ether-A-Go-Go Potassium Channels metabolism
ERG1 Potassium Channel antagonists & inhibitors
ERG1 Potassium Channel metabolism
Cardiac Conduction System Disease
Piperazines pharmacology
Piperazines chemistry
Piperazines chemical synthesis
Piperazines pharmacokinetics
Subjects
Details
- Language :
- English
- ISSN :
- 1520-4804
- Volume :
- 67
- Issue :
- 15
- Database :
- MEDLINE
- Journal :
- Journal of medicinal chemistry
- Publication Type :
- Academic Journal
- Accession number :
- 38757601
- Full Text :
- https://doi.org/10.1021/acs.jmedchem.4c00677